Source comparison
Physicochemical and delivery comparison
BPC-157 (~1419Da, highly soluble in water and saline, stable at −20°C lyophilised for approximately 24 months) is typically administered intraperitoneally or intravenously in research models. CNS penetration occurs through a combination of direct BBB crossing
This comparison does not assign a generated winner or score.
- BPC-157 (~1419Da, highly soluble in water and saline, stable at −20°C lyophilised for approximately 24 months) is typically administered intraperitoneally or intravenously in research models. CNS penetration occurs through a combination of direct BBB crossing at regions of increased permeability (injury-associated BBB disruption), vagal afferent signalling, and possible olfactory transport. The CNS pharmacokinetics of intact BPC-157 are less well-characterised than Semax — most CNS effects may be mediated indirectly through BPC-157’s vascular endothelial effects rather than direct neuronal receptor activation.
- Semax (~888Da, water-soluble, stable lyophilised at −20°C for approximately 24 months, reconstituted solutions at 4°C for approximately 7–14 days) is administered intranasally in most CNS research protocols. The olfactory route delivers peptide directly to olfactory receptor neurone dendrites (olfactory epithelium → olfactory bulb → limbic and cortical regions) and to the CSF via perineural spaces around the olfactory nerve. Intranasal bioavailability for CNS targets is approximately 3–5-fold more efficient (per mg administered) than i.p. for Semax, justifying the lower intranasal dose (50µg/kg) versus i.p. dose (150µg/kg) used in most mechanistic research.
- 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified BPC-157 and Semax for research and laboratory use. View UK stock →